The Marketed Health Products Directorate (MHPD), Therapeutic Products Directorate (TPD)
and Biologics and Genetic Therapies Directorate (BGTD) post safety alerts, public health
advisories, press releases and other notices from industry as a service to health professionals,
consumers, and other interested parties. Although MHPD, TPD and BGTD approve therapeutic products,
MHPD, TPD and BGTD do not endorse either the product or the company. Any questions regarding
product information should be discussed with your health professional.
This is duplicated text of a letter from AstraZeneca Canada Inc.
Contact the company for a copy of any references, attachments or enclosures. |
IMPORTANT DRUG SAFETY INFORMATION
Accelerated deaths using Casodex® (bicalutamide) 150 mg in patients with localized prostate
cancer otherwise undergoing watchful waiting
Health Canada has withdrawn its approval (Notice of Compliance with conditions) for CASODEX
150 mg. |
![Astrazeneca Logo](/web/20061212002143im_/http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/images/astrazeneca.jpg)
August 18, 2003
Dear Health Care Professional,
RECOMMENDATIONS: It is recommended that clinicians discontinue CASODEX 150 mg in
patients with localized prostate cancer
BASIS FOR CONCERN: Data from a planned second analysis of the Early Prostate Cancer (EPC)
trial program shows that at a median 5.4 years follow-up, in patients with localized prostate cancer
otherwise managed by watchful waiting and CASODEX 150 therapy, there was a trend towards
accelerated deaths compared to that of placebo.
RESULTS AND EXPOSURE: Patients otherwise undergoing watchful waiting were present in Trials 024
(European trial) and 025 (Scandinavian trial) only. There were no watchful waiting patients in Trial 023
(North American trial). In Trial 025, patients in the CASODEX arm received 4.6 yrs of therapy
compared with 3.4 years for placebo-treated patients. In Trial 024, patients received 3.8 years of
CASODEX 150 compared with 3.7 years for placebo patients. The overall results in patients with
localized prostate cancer otherwise managed by watchful waiting were [196 (25.2%) deaths vs 174
(20.5%) deaths, hazard ratio (HR) = 1.23, 95% CI 1.00, 1.50]. |
In November 2002, Health Canada granted a Notice of Compliance with Conditions (NOC/c) to CASODEX
150 mg, as immediate therapy in some patients with localized prostate cancer who are inappropriate for
surgery or radiation therapy. In this population, CASODEX 150 mg once daily oral therapy was recommended
for those who have a PSA doubling time less than ( < ) 5 years, Gleason grade greater than
( > ) 6, or PSA values greater than ( > ) 10. This conditional approval was based
on the promising nature of the clinical evidence in patients with this serious disease, and the need for
further follow up to verify the clinical benefit. Approval was based on time to objective progression
(surrogate endpoint).
AstraZeneca, following discussions with Health Canada, is alerting you to important emerging safety
information arising from a planned second analysis (5.4 yr median follow-up) of the Early Prostate Cancer
(EPC) trial programme. This international programme of 3 prospective, double blind, placebo-controlled
clinical trials (n=8113) compares CASODEX 150 mg vs. placebo, when given in addition to standard care in
men with localized or locally advanced non-metastatic prostate cancer. Thus patients received either
CASODEX or placebo as adjuvant therapy following primary therapy (radical prostatectomy or radiotherapy),
or as immediate therapy in men who would otherwise have been managed by watchful waiting (initiation of
therapy only if symptoms or signs of progression occurred). Primary endpoints are progression free survival
and overall survival.
For the progression free survival endpoint across the whole programme, there continues to be a
significant reduction in the risk of experiencing disease progression (HR 0.73, P< 0.0001) after 5.4
years of follow-up. However in view of the estimated median time to disease progression and median
survival of 7 and 10 years respectively for this class of patients, assessments have been made after
a relatively short follow-up period. Conclusion can only be made regarding early benefits or risks.
As seen in the first analysis (3.3 yr follow-up), in both adjuvant and watchful waiting settings,
benefits in terms of reduced risk of disease progression are largest in those with high risk of disease
progression (e.g., locally advanced disease, high PSA or high Gleason grade). Health Canada previously
assessed CASODEX 150 mg versus castration in the locally advanced patient population and found level 1
scientific evidence (one of the 2 randomized clinical trials) of accelerated deaths in CASODEX 150 mg
treated patients.
For overall survival, as with the first analysis, the second analysis showed no difference between
any treatment groups for the combined analysis or individual trials.
In exploratory sub-group analysis, some trends were seen in the watchful waiting patient subgroup.
A trend was observed towards a survival deficit in the subgroup of patients with localized disease
[196 (25.2%) deaths vs 174 (20.5%) deaths, HR = 1.23, 95% CI 1.00, 1.50]. This trend was mostly associated
with localized patients at low risk of disease progression. Conversely, in the higher risk subgroup of
patients with locally advanced disease, a trend towards a survival benefit was seen, [113(33.7%) deaths
vs. 133 (41.3%) deaths, HR = 0.80, 95% CI 0.62,1.04]. As indicated above, Health Canada has not approved
CASODEX 150 mg for locally advanced prostate cancer.
Patients treated in the adjuvant setting show no differences in survival, though survival data in this
setting are still relatively immature at this time (approximately 10% deaths in adjuvant setting).
In view of these data, and in the absence of factors to suggest high risk of disease progression, it
is recommended that clinicians discontinue CASODEX 150 mg in patients with localized prostate cancer
otherwise undergoing watchful waiting. It should be noted that metastatic prostate cancer patients taking
CASODEX 50 mg per day are not affected by the new information.
The identification, characterization and management of marketed health product- related adverse
reactions are dependent on the active participation of health care professionals in adverse reactions
reporting programmes. Any occurrences of accelerated deaths or other serious and/or unexpected adverse
reactions in patients receiving CASODEX 150 mg should be reported to AstraZeneca at the following address:
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y IM4
Drug Safety Tel: 1-800 433-0733 and Fax: 1-800 267-5743
Your professional commitment in this regard has an important role in protecting the well-being of
your patients by contributing to early signal detection and informed drug use.
Sincerely,
original signed by
Kazimierz R. Borkowski, Ph.D.
Vice President, Medical Affairs
AstraZeneca Canada Inc.
Any suspected adverse incident can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR
Guidelines can be found on the TPD web site or in The Canadian
Compendium of Pharmaceuticals and Specialties.
|
|